Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

October 24, 2020

Study Completion Date

January 12, 2021

Conditions
Reflux Esophagitis
Interventions
DRUG

X842

X842 capsules

DRUG

X842 Placebo

X842 placebo-matching capsules

DRUG

Lansoprazole

Lansoprazole capsules

DRUG

Lansoprazole Placebo

Lansoprazole placebo-matching capsules

Trial Locations (16)

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

101100

Beijing Luhe Hospital Capital Medical University, Beijing

210006

Nanjing First Hospital, Nanjing

213003

The First people's Hospital of Changzhou, Changzhou

233004

The First Affiliated Hospital of Bengbu Medical College, Bengbu

237016

Liuan People's Hospital, Liu‘an

250013

Jinan Central Hospital, Jinan

250065

Tongji Hospital of Tongji University, Shanghai

256600

Binzhou Medical University Hospital, Binzhou

318000

Taizhou Municipal Hospital, Taizhou

337000

Jiangxi PingXiang People's Hospital, Pingxiang

400010

The Second Affiliated Hospital of Chongqi Medical University, Chongqing

410008

Xiangya Hospital Central South University, Changsha

423000

Affiliated Hospital of Xiangnan University, Chenzhou

550004

The Affiliated Hospital of Guzihou Medical University, Guiyang

563000

Affiliated Hospital of Zunyi Medical University, Zunyi

All Listed Sponsors
lead

Jiangsu Sinorda Biomedicine Co., Ltd

INDUSTRY

NCT04531475 - Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis | Biotech Hunter | Biotech Hunter